Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3142 in Advanced Malignant Tumors
NCT07338838Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3142 in cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Phase II Recommended Doses at 24 months, Dose-Limiting Toxicity at 1 month and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
TQB3142
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07338838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07338838.